bluuebunny/crossref_metadata_2025_split huggingface dataset:
A hybrid approach of gravitational search algorithm and ant miner plus for fingerprint recognition
Authors: Kumar Mahesh , Kumar Devender 
Published: August 2022

The gravitational search algorithm (GSA) is an eminent heuristic algorithm inspired by the laws of gravity and motion. It possesses an independent physical model in which the mass agents are guided by gravitational force to quickly achieve the convergence. Although the GSA is proven to be efficient for science and engineering problems, the mass agents can be trapped in premature convergence due to the heaviness of masses in the later iterations. The occurrence of premature convergence impedes the agents’ further exploration of the search space for a better solution. Here, the ant miner plus (AMP) variant of the ant colony optimization (ACO) algorithm is utilized to avoid the trapping of agents in local optima. The AMP algorithm extends the exploration ability of the GSA algorithm by using the attributes of pheromone updating rules generated by best ants and a problem-dependent heuristic function. The AMP variant adheres to the attributes of the ACO algorithm and is also a decision-making variant which determines the problem solution more efficiently by constructing a directed acyclic graph, considering class-specific heuristic values, and including weight parameters for the pheromone and heuristic values. In this research, this hybridization of GSA and AMP (GSAMP) algorithms is presented, and it is utilized for the decision-making application of fingerprint recognition. Here, fingerprint recognition is conducted for complete as well as latent fingerprints, which are poor quality partial fingerprints, mostly acquired from crime scenes by law enforcement agencies. The experiments are performed for the complete fingerprint dataset of FVC2004 and the latent fingerprint dataset of NIST SD27, using the proposed GSAMP approach and the individual algorithms of Ant Miner (AM) and AMP. The experimental evaluation indicates the superiority of the proposed approach compared to other methods.
Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth
Authors: Alam Shamshad , Zunic Amanda , Venkat Swati , Feigin Michael E. , Atanassov Boyko S. 
Published: August 2022

Abstract

Cyclin D1 (CCND1) is a critical regulator of cell proliferation and its overexpression has been linked to the development and progression of several malignancies. CCND1 overexpression is recognized as a major mechanism of therapy resistance in several cancers; tumors that rely on CCND1 overexpression to evade cancer therapy are extremely sensitive to its ablation. Therefore, targeting CCND1 is a promising strategy for preventing tumor progression and combating therapy resistance in cancer patients. Although CCND1 itself is not a druggable target, it can be targeted indirectly by inhibiting its regulators. CCND1 steady-state levels are tightly regulated by ubiquitin-mediated degradation, and defects in CCND1 ubiquitination are associated with increased CCND1 protein levels in cancer. Here, we uncover a novel function of ubiquitin-specific protease 27X (USP27X), a deubiquitinating enzyme (DUB), in regulating CCND1 degradation in cancer. USP27X binds to and stabilizes CCND1 in a catalytically dependent manner by negatively regulating its ubiquitination. USP27X expression levels correlate with the levels of CCND1 in several HER2 therapy–resistant breast cancer cell lines, and its ablation leads to a severe reduction of CCND1 protein levels, inhibition of tumor growth, and resensitization to targeted therapy. Together, the results presented in our study are the first to expose USP27X as a major CCND1 deubiquitinase and provide a mechanistic explanation for how this DUB fosters tumor growth.

Implications:
As a deubiquitinating enzyme, USP27X is a druggable target. Our study illuminates new avenues for therapeutic intervention in CCND1-driven cancers.
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy
Authors: Trivedi Meghna S. , Arber Nadir , Friedman Eitan , Garber Judy E. , Holcomb Kevin , Horowitz Neil S. , Wright Jason D. , Lee J. Jack , Vornik Lana A. , Abutaseh Saba , Castile Tawana , Sauter Edward R. , Dimond Eileen , Heckman-Stoddard Brandy M. , House Margaret , Samimi Goli , Brown Powel H. , Crew Katherine D. 
Published: August 2022

Abstract
Female carriers of pathogenic/likely pathogenic (P/LP) BRCA1/2 variants are at increased risk of developing breast and ovarian cancer. Currently, the only effective strategy for ovarian cancer risk reduction is risk-reducing bilateral salpingo-oophorectomy (RR-BSO), which carries adverse effects related to early menopause. There is ongoing investigation of inhibition of the RANK ligand (RANKL) with denosumab as a means of chemoprevention for breast cancer in carriers of BRCA1 P/LP variants. Through the NCI Division of Cancer Prevention (DCP) Early Phase Clinical Trials Prevention Consortia, a presurgical pilot study of denosumab was developed in premenopausal carriers of P/LP BRCA1/2 variants scheduled for RR-BSO with the goal of collecting valuable data on the biologic effects of denosumab on gynecologic tissue. The study was terminated early due to the inability to accrue participants. Challenges which impacted the conduct of this study included a study design with highly selective eligibility criteria and requirements and the COVID-19 pandemic. It is critical to reflect on these issues to enhance the successful completion of future prevention studies in individuals with hereditary cancer syndromes.
Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition
Authors: MacFarland Suzanne P. , Maese Luke , Rednam Surya P. , Kamihara Junne , Perrino Melissa R. , Nichols Kim E. , Brodeur Garrett M. , Schiffman Joshua D. , Plon Sharon E. , Diller Lisa R. , Malkin David , Porter Christopher C. , Villani Anita 
Published: August 2022

AbstractGermline pathogenic variants in cancer susceptibility genes are identified in up to 18% of all children with cancer. Because pediatric cancer predisposition syndromes (CPS) themselves are rare and underrecognized, there are limited data to guide the diagnosis and management of affected children and at-risk relatives. Furthermore, the care of affected children requires distinct considerations given the early onset of cancers, lifelong risks of additional cancers, and potential late effects of therapy. Herein, we discuss efforts to leverage existing infrastructure, organize experts, and develop a new consortium to optimize care and advance research for children with CPS. A 2016 workshop organized by the American Association for Cancer Research united many experts in childhood cancer predisposition and resulted in publication of multiple consensus guidelines for tumor surveillance. More recently, several of these authors established the Consortium for Childhood Cancer Predisposition (C3P), a multi-institutional collaboration that provides a structure for systematic research in cancer predisposition, screening, and prevention in children. The Consortium intends to work with other cooperative groups to merge longitudinal data from children with CPS throughout the continuum of the cancer risk period, as well as cancer treatment and survivorship care, to optimize overall outcomes.
Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
Authors: Shore Supriya , Basu Tanima , Kamdar Neil , Brady Patrick , Birati Edo , Hummel Scott L. , Chopra Vineet , Nallamothu Brahmajee K. 
Published: August 2022

Background
Current guidelines recommend use of sacubitril‐valsartan in patients with heart failure with reduced ejection fraction (HFrEF). Early data suggested low uptake of sacubitril‐valsartan, but contemporary data on real‐world use and their associated cost are limited.

Methods and Results

This was a retrospective study of individuals enrolled in Optum Clinformatics, a national insurance claims data set from 2016 to 2018. We included all adult patients with HFrEF with 2 outpatient encounters or 1 inpatient encounter with an
International Classification of Diseases, Tenth Revision
(
ICD‐10
), diagnosis of HFrEF and 6 months of continuous enrollment, also receiving β‐blockers and angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers within 6 months of HFrEF diagnosis. We included 70 245 patients with HFrEF, and 5217 patients (7.4%) received sacubitril‐valsartan prescriptions. Patients receiving care through a cardiologist compared with a primary care physician alone were more likely to receive sacubitril‐valsartan (odds ratio, 1.61 [95% CI, 1.52–1.71]). Monthly out‐of‐pocket (OOP) cost for sacubitril‐valsartan, compared with angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, was higher for both commercially insured patients (mean, $69 versus $6.74) and Medicare Advantage (mean, $62 versus $2.52). For patients with commercial insurance, OOP cost was lower in 2016 than in 2018. For patients with Medicare Advantage, there was a significant geographic variation in the OOP costs across the country, ranging from $31 to $68 per month across different regions, holding all other patient‐related factors constant.

Conclusions
Sacubitril‐valsartan use was infrequent among patients with HFrEF. Patients receiving care with a cardiologist were more likely to receive sacubitril‐valsartan. OOP costs remain high, potentially limiting use. Significant geographic variation in OOP costs, unexplained by patient factors, was noted.
Age and Sex Differences and Temporal Trends in the Use of Invasive and Noninvasive Procedures in Patients Hospitalized With Acute Myocardial Infarction
Authors: Tran Vu Hoang , Mehawej Jordy , Abboud Donna M. , Tisminetzky Mayra , Hariri Essa , Filippaios Andreas , Gore Joel M. , Yarzebski Jorge , Goldberg Jordan H. , Lessard Darleen , Goldberg Robert 
Published: August 2022

Background
Few studies have examined age and sex differences in the receipt of cardiac diagnostic and interventional procedures in patients hospitalized with acute myocardial infarction and trends in these possible differences during recent years.

Methods and Results
Data from patients hospitalized with a first acute myocardial infarction at the major medical centers in the Worcester, Massachusetts, metropolitan area were utilized for this study. Logistic regression analysis was used to examine age (<55, 55–64, 65–74, and ≥75 years) and sex differences in the receipt of echocardiography, exercise stress testing, coronary angiography, percutaneous coronary interventions, and coronary artery bypass graft surgery, and trends in the use of those procedures during patients' acute hospitalization, between 2005 and 2018, while adjusting for important confounding factors. The study population consisted of 1681 men and 1154 women with an initial acute myocardial infarction who were hospitalized on an approximate biennial basis between 2005 and 2018. A smaller proportion of women underwent cardiac catheterization, percutaneous coronary intervention, and coronary artery bypass graft surgery, while there were no sex differences in the receipt of echocardiography and exercise stress testing. Patients aged ≥75 years were less likely to undergo cardiac catheterization, percutaneous coronary intervention, and coronary artery bypass graft surgery, but were more likely to receive echocardiography compared with younger patients. Between 2005 and 2018, the use of echocardiography and coronary artery bypass graft surgery nonsignificantly increased among all age groups and both sexes, while the use of cardiac catheterization and percutaneous coronary intervention increased nonsignificantly faster in women and older patients.

Conclusions
We observed a continued lower receipt of invasive cardiac procedures in women and patients aged ≥75 years with acute myocardial infarction, but age and sex gaps associated with these procedures have narrowed during recent years.
Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis
Authors: Nagraj Sanjana , Varrias Dimitrios , Hernandez Romero Gabriel , Santos Heitor T. , Karamanis Dimitrios , Sagris Dimitrios , Korompoki Eleni , Milionis Haralampos , Palaiodimos Leonidas , Ntaios George 
Published: August 2022

Background:
COVID-19 has been frequently associated with an increased risk of thrombotic complications. There have also been reports of an increased likelihood of stroke, although its true incidence in patients with COVID-19 is currently unknown.

Methods:
Electronic databases PubMed and Scopus were searched from inception up to July 30, 2021 to identify randomized controlled studies in patients with confirmed COVID-19 undergoing one or more interventions. Studies were screened for eligibility using a predefined inclusion criterion and selected using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A random-effects model meta-analysis was conducted, and heterogeneity was assessed using I-squared test.

Results:
Out of 3960 potentially eligible articles, 77 randomized studies (38 732 patients) were included. Mean age of the study population was 55±9.3 years. Females constituted 38% of the study population and mean duration of follow-up after study enrollment was 23±12.9 days. Cumulative incidence of stroke in the overall study population was 0.001 (95% CI, 0.001–0.002) with a total of 65 events in 38 732 patients, corresponding to an absolute incidence of 0.168%. Incidence of stroke in the inpatient population was 0.001 (95% CI, 0.001–0.002; 65 events in 37 069 patients), corresponding to an absolute incidence of 0.175%. No strokes were observed in the outpatient setting.

Conclusions:
The overall incidence of stroke in patients with COVID-19 appears to be lower than that reported in previous observational reports.
An Analytical Psychology Conceptualisation of Psychosis in Modern Psychiatry
Authors: Howe Andrew John , Demjaha Arsime 
Published: August 2022

Abstract
Analytic formulation and contribution to treatment of psychotic disorders have little application in modern psychiatry. The medical model, largely based on psychopharmacology and biological conceptualisation of illness, particularly dominates the treatment of psychosis. While many analysts have worked with patients in psychotic states, it is rare to find analytic approaches to psychosis within the national health service (NHS) in the UK. We feel this a detriment to a sometimes difficult to treat patient group. Jung spent his early working years devoted to patients with psychosis at the Burgholzli hospital in Zurich. Later on in his career, Jung had personal experience of psychotic symptoms, interacting with visions and voices within his own mind, that are noted in his posthumous Red Book. Jung is, therefore, arguably one of the most experienced analysts and depth psychologists in the realm of psychosis. In this paper we describe Jung’s in-depth psychological approach to the genesis of psychosis. We then discuss parallels with our contemporary understanding of the aetiology of psychosis. Our aim is to highlight the importance of an analytical approach and thinking in a) understanding the aetiology and b) contribution to treatment of such a complex and intractable disorder as psychosis.
The Nexus Between Remittance Inflows and Financial Development in India: Substitutes or Complements?
Authors: Deheri Abdhut 
Published: August 2022

This article investigates the relationship between remittance inflows and financial development in India from 1980 to 2018. The study employed Autoregressive Distributed Lag (ARDL) and Vector Error Correction (VEC) models to capture the short and long-run dynamics. In addition, the impulse response function (IRF) and forecast error variance decomposition (FEVD) analysis were utilised to understand the dynamic reaction of financial development to a given shock to remittance inflows and other variables. The results of the ARDL model reveal that remittances negatively influence financial development in the short run, while they positively influence it in the long run. The IRF analysis shows that financial development responds positively to one standard positive shock to remittance inflows. The FEVD analysis further reveals that shocks to remittance inflows explain around 30% to 32% of the total variation in financial development. From a policy standpoint, the findings suggest that well-framed policies should be formulated and implemented to encourage more remittance flows through formal channels. It will boost financial development, economic growth and also increase the other developmental effects of remittances on the economy. JEL Codes: C32, F22, F37
All Things Are Like a Horse, or Radical Posthumanism: A Daoist Ethics for the Anthropocene and Beyond
Authors: Liao Sebastian Hsien-hao 
Published: August 2022

AbstractThis article explores how Chinese Daoist thought can address the need of an ethics that can cope with “the Anthropocene.” It explores the similarities between Daoist thought and posthumanist theories which arose partially as a response to the challenges of the Anthropocene. And it examines how Daoist thought can radicalize posthumanist thinking by means of an ethics based on a genuinely flat ontology that treats all things, human and nonhuman, as equal.
Effect of LncRNA OIP5-AS1/microRNA-186-5p on isoflurane-induced cognitive dysfunction in aged rats
Authors: Sun Yujing , Yuan Yawei , Wang Long , Sun Sen 
Published: August 2022

Background Post-operative recognition dysfunction (POCD) is a kind of central nervous system complication that appears after operative anesthesia. Recent studies on the mechanism of long non-coding RNA (lncRNA) in neurodegenerative diseases are abundant. Aims The study aimed to explore the expression pattern and role of lncRNA OIP5-AS1 in POCD and to investigate its underlying mechanism in old rats. Methods The old rats were exposed to isoflurane to mimic the POCD in the elderly, and their cognitive function was tested via Morris water maze (MWM) test. Enzyme linked immunosorbent assay was applied for the concentration detection of inflammation and oxidative stress-related factors. Luciferase reporter assay was done for the target gene analysis. Results Downregulation of OIP5-AS1 was accompanied by isoflurane treatment in rats, overexpression of OIP5-AS1 induced the rats to spend more time in the target quadrant, and shorten escape latency time. OIP5-AS1 inhibited the release of TNF-α, IL-6 and IL-1β, GSH and superoxide dismutase, decreased the activation of caspase-3, but promoted malondialdehyde release. miR-186-5p was a target miRNA of OIP5-AS1, and exhibited high expression in rats after isoflurane exposure. miR-186-5p can abolish the beneficial role of OIP5-AS1 against cognitive impairment, inflammatory response, oxidative stress and neuron apoptosis. Conclusion OIP5-AS1 plays a neuroprotective role in elderly POCD rats through sponging miR-186-5p, and it is related to OIP5-AS1/miR-186-5p mediated inflammatory response, oxidative stress and neuron apoptosis.
The protective effects of ritodrine against hypoxia/reoxygenation-induced injury in endometrial stromal cells
Authors: Zhu Jing , Liu Haiyun , Mao Lijing 
Published: August 2022

Endometriosis (EMS) is often observed in women of childbearing age and significantly impacts patients’ quality of life. Ritodrine is a β2 receptor agonist applied for relaxing the uterine smooth muscle. Its inhibitory effects on inflammation have recently been noted. The present study explored the protective impact of Ritodrine on hypoxia/reoxygenation (H/R)- induced injury in endometrial stromal cells (ESCs). Human ESCs (HESCs) were treated with Ritodrine (0.1, 0.5 μM) for 24 h, followed by exposure to H/R for 6 h. Ritodrine ameliorated H/R-induced higher reactive oxygen species (ROS), declined glutathione (GSH) concentration and increased production of tumor necrosis factor-α (TNF-α), interleukin- 6 (IL-6), and monocyte chemotactic protein 1 (MCP-1) in HESCs. Furthermore, Ritodrine ameliorated the H/R-induced higher nuclear level of nuclear factor κ-B (NF-κB) p65 expression and increased luciferase activity of the NF-κB promoter. In addition, we show that Ritodrine mitigated H/R-induced higher estrogen receptor α (ER-α) expression in HESCs. Interestingly, overexpressing ER-α abolished the regulatory effects of Ritodrine on oxidative stress and the NF-κB pathway-mediated inflammation. Collectively, our data reveal that Ritodrine alleviated H/R-induced injury in ESCs by inhibiting the ER-α/NF-κB pathway.
Assessment of chemotherapy-related educational needs of colorectal cancer patients
Authors: Tezcan Songul , Tanır Gökçen İlke , Yılmaz Hayriye , Memiş Semra , Yumuk Perran Fulden , Apikoğlu Şule 
Published: August 2022

Aim Aim of our study was to evaluate cancer patients’ knowledge about their chemotherapy regimens in order to assess educational needs of patients. Methods Study was conducted on 58 colorectal carcinoma patients who were treated in an outpatient chemotherapy unit. These patients had received a 2-page information pamphlet about their chemotherapy treatments before the commencement of treatment. During the first interview with patients, pharmacist collected demographic data and evaluated patients’ knowledge about their medications using a standardized questionnaire. Findings Mean age of the patients was 59.6 ± 1.3 years; 65.5% were male. Majority (77.6%) of patients were graduates of primary school. Sixty-four percent of these had at least one comorbid disease. Median number of chemotherapy courses already received by patients was 4 (1–9). Fifty-nine percent reported that they did not receive any patient education and 43.1% reported that they did not receive any informative document. Twenty-nine percent of patients did not know what actions to take in case of nausea-vomiting; while 53.4% did not know how to react if their body temperature exceeded 38 °C and 25.9% had no idea about dietary necessities. About one-third of patients did not pay attention to oral care. Conclusion Our study showed that patients did not understand (or remember) the basic points about their chemotherapy sufficiently, but remembered the adverse effects they experienced occasionally. Pharmacists will have the chance to increase the level of knowledge of the patients receiving chemotherapy by providing patient education and follow-up.